Compare SMTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | CLLS |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.5M | 394.4M |
| IPO Year | 2008 | 2014 |
| Metric | SMTI | CLLS |
|---|---|---|
| Price | $34.19 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $34.00 | $8.33 |
| AVG Volume (30 Days) | ★ 344.1K | 15.5K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $12.48 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $2.35 |
| 52 Week High | $35.70 | $5.48 |
| Indicator | SMTI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 81.05 | 63.18 |
| Support Level | $20.47 | $3.12 |
| Resistance Level | $34.33 | $3.40 |
| Average True Range (ATR) | 0.74 | 0.15 |
| MACD | 0.14 | 0.05 |
| Stochastic Oscillator | 97.65 | 100.00 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.